GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aptahem AB (XSAT:APTA) » Definitions » Cyclically Adjusted Price-to-FCF

Aptahem AB (XSAT:APTA) Cyclically Adjusted Price-to-FCF : (As of Jun. 06, 2025)


View and export this data going back to 2015. Start your Free Trial

What is Aptahem AB Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Aptahem AB Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Aptahem AB's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aptahem AB Cyclically Adjusted Price-to-FCF Chart

Aptahem AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Aptahem AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Aptahem AB's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Aptahem AB's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aptahem AB's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aptahem AB's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Aptahem AB's Cyclically Adjusted Price-to-FCF falls into.


;
;

Aptahem AB Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Aptahem AB's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Aptahem AB's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=-0.183/132.8245*132.8245
=-0.183

Current CPI (Mar. 2025) = 132.8245.

Aptahem AB Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 -15.089 99.995 -20.043
201509 -13.975 100.228 -18.520
201512 -21.602 100.276 -28.614
201603 -21.111 100.751 -27.831
201606 -24.802 101.019 -32.611
201609 -12.534 101.138 -16.461
201612 -17.137 102.022 -22.311
201703 -16.077 102.022 -20.931
201706 -16.893 102.752 -21.837
201709 -53.195 103.279 -68.413
201712 -14.019 103.793 -17.940
201803 -31.247 103.962 -39.922
201806 -30.341 104.875 -38.427
201809 -2.323 105.679 -2.920
201812 0.323 105.912 0.405
201903 -11.043 105.886 -13.852
201906 -4.915 106.742 -6.116
201909 -4.347 107.214 -5.385
201912 -7.038 107.766 -8.675
202003 -0.425 106.563 -0.530
202006 -5.238 107.498 -6.472
202009 -7.030 107.635 -8.675
202012 -12.193 108.296 -14.955
202103 -15.000 108.360 -18.387
202106 -10.704 108.928 -13.052
202109 -2.887 110.338 -3.475
202112 -4.288 112.486 -5.063
202203 12.766 114.825 14.767
202206 -7.231 118.384 -8.113
202209 -0.565 122.296 -0.614
202212 1.125 126.365 1.183
202303 -2.427 127.042 -2.537
202306 -1.061 129.407 -1.089
202309 -2.737 130.224 -2.792
202312 0.276 131.912 0.278
202403 -1.709 132.205 -1.717
202406 -0.334 132.716 -0.334
202409 -0.295 132.304 -0.296
202412 -0.218 132.987 -0.218
202503 -0.183 132.825 -0.183

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Aptahem AB  (XSAT:APTA) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Aptahem AB Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Aptahem AB's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Aptahem AB Business Description

Industry
Traded in Other Exchanges
N/A
Address
Norra Vallgatan 58, Malmo, SWE, 211 22
Aptahem AB develops aptamer-based drugs for the treatment of acute life-threatening conditions where coagulation and inflammation interact in the disease process. The company's main candidate Apta-1 is developed as an emergency medicine intended to prevent the occurrence of life-threatening organ and tissue damage in patients suffering from sepsis.

Aptahem AB Headlines

No Headlines